Previous 10 | Next 10 |
home / stock / mrk / mrk articles
Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transa...
Merck & Co (NYSE:MRK) has announced an acquisition of Harpoon Therapeutics (NASDAQ:HARP) that is expected to be completed 2024-H1. Under the te...
Merck & Co Inc (NYSE: MRK) is reportedly negotiating to purchase cancer drugmaker Harpoon Therapeutics Inc (NASDAQ: HARP) f...
Surprisingly, it is not Big Tech that kicked off 2024 but healtchare champions. Moderna Inc (NASDAQ: MRNA) shares rose after Oppenheimer ...
Around 15% of Americans said they were planning to participate this year in Dry January — a month of abstinence from alcohol — according to a s...
In the current session, the stock is trading at $117.10, after a 0.08% increase. Over the past month, Merck & Co Inc. (NYSE:MRK) stock increase...
On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners named Merck & Co., Inc. (NYSE: MRK)...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 09:30:00 ET The Dow Jones Industrial Average has long been a bellwether for the overall health of the U.S. stock market, tracking 30 large publicly owned companies across various sectors. While the index has seen modest gains in 2024, one of its constituents has been signific...
Clesrovimab met all primary safety and efficacy endpoints Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from its Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab (MK-1654), the company’s investigati...
2024-07-18 04:59:00 ET Some might hesitate to invest in stocks during a bull run, like the one we are experiencing. They argue that equities are likely to be overvalued. However, it's possible to find reasonably valued picks in this environment, even among top high-quality stocks. And some ...